TURKU, Finland I March 21, 2013 I Biotie announced today that full data from a Phase 2b study evaluating tozadenant (SYN115) in Parkinson’s disease (PD) patients experiencing levodopa related end of dose wearing off were presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, March 20, 2013. These data were selected by the AAN for the Emerging Science Program (formerly Late-breaking Science Program) and were presented by Dr. C. Warren Olanow, Professor of Neurology and Neuroscience at the Mount Sinai School of Medicine.
The study was an international, 12-week, double-blind, phase 2 trial in which patients on stable dosages of levodopa with at least 2.5 hours (hr) of OFF time per day were randomized to tozadenant 60, 120, 180 or 240 mg BID, or matching placebo. The primary outcome measure was the change from baseline to Week 12 in hours per day spent in the OFF state. A mixed-model repeated-measures ANCOVA was used for analyses with a pre-specified hierarchical step-down approach to test multiple dose groups.
Of 420 patients randomized, 337 completed treatment. Their mean age was 63.3 years, mean duration of PD 8.7 years, and their mean OFF time at baseline was about 6 hr/day. Significant reductions in mean placebo-corrected change from baseline in OFF time were observed with tozadenant (modified Intention to Treat population) 120 mg BID (-1.1 hr, p=0.0039) and 180 mg BID (-1.2 hr, p=0.0039). The amount of time patients spent in the ON time with troublesome dyskinesia was not significantly increased in any tozadenant group. Mean placebo-corrected scores on the Unified Parkinson’s Disease Rating Scale (UPDRS) part III significantly improved with tozadenant 120 mg BID (-2.2, p=0.0325) and 180 mg BID (-2.5, p=0.0325), and mean placebo-corrected UPDRS I-III scores improved significantly in all tozadenant groups (all groups, p < 0.03) The changes were also perceptible to both physicians and patients, as reflected in statistically significant improvements on global ratings. Mean placebo-corrected scores on the clinician-administered global impressions of severity (CGI-S) and improvement (CGI-I) improved significantly in all tozadenant groups, and placebo-corrected scores on patient ratings (Patient Global Impression; PGI) significantly improved in the 120 mg BID group. The most common adverse events in the combined tozadenant groups were dyskinesia, nausea, dizziness, constipation, PD worsening, insomnia and falls.
Steve Bandak, Chief Medical Officer of Biotie stated, "We are very pleased that these data were selected for inclusion in AAN’s Emerging Science Program and believe it reflects the scientific importance of these findings and the potential opportunity for tozadenant as a new treatment for Parkinson’s disease". He continued, "We are now working closely with our partner UCB Pharma for further development of tozadenant and plan to start the phase 3 program by H1 2015".
ABOUT TOZADENANT
Tozadenant is an orally administered, selective inhibitor of the adenosine 2a (A2a) receptor being developed initially for the treatment of Parkinson’s disease. A2a receptors are expressed in high concentration in the striatum of the brain and are thought to play an important role in regulating motor function. Tozadenant blocks the effect of endogenous adenosine at the A2a receptors, resulting in the potentiation of the effect of dopamine and inhibition of the effect of glutamate at the mGluR5 receptor. Biotie has granted UCB Pharma S.A. a license for exclusive, worldwide rights to tozadenant.
ABOUT BIOTIE
Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson’s disease, Alzheimer’s disease and other cognitive disorders, alcohol and drug dependence (addiction) and post-traumatic stress disorder), and inflammatory and fibrotic liver disease. The company has a strong and balanced development portfolio with several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential.
Biotie’s most advanced product, Selincro™ (nalmefene), licensed to Lundbeck A/S, has on 28 February 2013 received European marketing authorization for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high level of alcohol consumption. In addition, Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant which is transitioning into Phase 3 development for Parkinson’s disease.
SOURCE: Biotie
Post Views: 278
TURKU, Finland I March 21, 2013 I Biotie announced today that full data from a Phase 2b study evaluating tozadenant (SYN115) in Parkinson’s disease (PD) patients experiencing levodopa related end of dose wearing off were presented at the 65th Annual Meeting of the American Academy of Neurology (AAN) in San Diego, March 20, 2013. These data were selected by the AAN for the Emerging Science Program (formerly Late-breaking Science Program) and were presented by Dr. C. Warren Olanow, Professor of Neurology and Neuroscience at the Mount Sinai School of Medicine.
The study was an international, 12-week, double-blind, phase 2 trial in which patients on stable dosages of levodopa with at least 2.5 hours (hr) of OFF time per day were randomized to tozadenant 60, 120, 180 or 240 mg BID, or matching placebo. The primary outcome measure was the change from baseline to Week 12 in hours per day spent in the OFF state. A mixed-model repeated-measures ANCOVA was used for analyses with a pre-specified hierarchical step-down approach to test multiple dose groups.
Of 420 patients randomized, 337 completed treatment. Their mean age was 63.3 years, mean duration of PD 8.7 years, and their mean OFF time at baseline was about 6 hr/day. Significant reductions in mean placebo-corrected change from baseline in OFF time were observed with tozadenant (modified Intention to Treat population) 120 mg BID (-1.1 hr, p=0.0039) and 180 mg BID (-1.2 hr, p=0.0039). The amount of time patients spent in the ON time with troublesome dyskinesia was not significantly increased in any tozadenant group. Mean placebo-corrected scores on the Unified Parkinson’s Disease Rating Scale (UPDRS) part III significantly improved with tozadenant 120 mg BID (-2.2, p=0.0325) and 180 mg BID (-2.5, p=0.0325), and mean placebo-corrected UPDRS I-III scores improved significantly in all tozadenant groups (all groups, p < 0.03) The changes were also perceptible to both physicians and patients, as reflected in statistically significant improvements on global ratings. Mean placebo-corrected scores on the clinician-administered global impressions of severity (CGI-S) and improvement (CGI-I) improved significantly in all tozadenant groups, and placebo-corrected scores on patient ratings (Patient Global Impression; PGI) significantly improved in the 120 mg BID group. The most common adverse events in the combined tozadenant groups were dyskinesia, nausea, dizziness, constipation, PD worsening, insomnia and falls.
Steve Bandak, Chief Medical Officer of Biotie stated, "We are very pleased that these data were selected for inclusion in AAN’s Emerging Science Program and believe it reflects the scientific importance of these findings and the potential opportunity for tozadenant as a new treatment for Parkinson’s disease". He continued, "We are now working closely with our partner UCB Pharma for further development of tozadenant and plan to start the phase 3 program by H1 2015".
ABOUT TOZADENANT
Tozadenant is an orally administered, selective inhibitor of the adenosine 2a (A2a) receptor being developed initially for the treatment of Parkinson’s disease. A2a receptors are expressed in high concentration in the striatum of the brain and are thought to play an important role in regulating motor function. Tozadenant blocks the effect of endogenous adenosine at the A2a receptors, resulting in the potentiation of the effect of dopamine and inhibition of the effect of glutamate at the mGluR5 receptor. Biotie has granted UCB Pharma S.A. a license for exclusive, worldwide rights to tozadenant.
ABOUT BIOTIE
Biotie is a specialized drug development company focused on the development of drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson’s disease, Alzheimer’s disease and other cognitive disorders, alcohol and drug dependence (addiction) and post-traumatic stress disorder), and inflammatory and fibrotic liver disease. The company has a strong and balanced development portfolio with several innovative small molecule and biological drug candidates at different stages of clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential.
Biotie’s most advanced product, Selincro™ (nalmefene), licensed to Lundbeck A/S, has on 28 February 2013 received European marketing authorization for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high level of alcohol consumption. In addition, Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant which is transitioning into Phase 3 development for Parkinson’s disease.
SOURCE: Biotie
Post Views: 278
